Contact Us
20 Feb 2026
Go Back

High infection rates achieved with the world’s first RSV B challenge model: a key component of our RSV-hMPV combination vaccine efficacy testing platform

Share this:

Other recent posts

If you’re a potential customer, job seeker, health professional or an investor, find out how hVIVO can help you.

Contact hVIVO

Stay connected

Sign up to our emails and follow us on social media to keep up to date with hVIVO.

By clicking Sign Up you're confirming that you agree with our Privacy Policy.
chevron-downarrow-up